Skip to content

Smartphone app for heart attack patients- A Clinical Trial

Smartphone based application for drug adherence and risk factor modification in outpatients with coronary artery disease â?? an open label randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/12/038617
Enrollment
178
Registered
2021-12-14
Start date
Unknown
Completion date
Unknown
Last updated
2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I259- Chronic ischemic heart disease, unspecified

Interventions

Intervention1: Active App: Active App will be customised based on patient profile and risk factors
will actively interact with the patient through alerts, reminders and warnings, based on automatically captured data (steps per day, inactivity, sleep per day, clicks on stress and medication screens)

Sponsors

JIPMER Alumni Association of North America
Lead Sponsor
Jawaharlal Institute of Postgraduate Medical Education and Research
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients with clinically documented stable CAD attending cardiology OPD of JIPMER hospital. 2. 18 years to 64 years 3. Able to use a smart phone with android function 4. Able to read English or Tamil

Exclusion criteria

Exclusion criteria: 1. Recent ACS or PCI within 1 month 2. Patients awaiting revascularization 3. Has visual, auditory, cognitive or motor impairment 4. LVEF 5. COPD, Peripheral Vascular Disease, Post Pacemaker 6. Recent CABG within 6 months.

Design outcomes

Primary

MeasureTime frame
Medication adherence will be measured by assessing the number of adherence failure events (defined as 1 missed dose during a observation cycle of 30 days) using pill counting method and Medication adherence score. Improvement of CV risk factor targets (defined before). Timepoint: Medication adherence will be measured by assessing the number of adherence failure events (defined as 1 missed dose during a observation cycle of 30 days) using pill counting method. Improvement of CV risk factor targets (defined before).

Secondary

MeasureTime frame
Change in Quality of Life, Stress level and Quality of sleep are the secondary outcomes measured at baseline, 12 weeks and 24 weeksTimepoint: 3

Countries

India

Contacts

Public ContactDr Saurav Banerjee

Jawaharlal Institute of Postgraduate Medical Education and Research

drsanthoshsatheesh@gmail.com9443426244

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026